Astrazeneca (AZN) Non Operating Interest Expenses (2009 - 2026)

Astrazeneca has reported Non Operating Interest Expenses for 18 years, with the latest figure at -$435.0 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 0.91% year-over-year to -$435.0 million in Q2 2026; TTM through Jun 2026 was -$3.0 billion, a 76.88% decrease from a year earlier, with the FY2025 full-year figure at -$1.7 billion, up 2.76% from the prior year.
• Non Operating Interest Expenses was -$435.0 million for Q2 2026 at Astrazeneca, down from -$393.0 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was -$311.0 million in Q2 2022, with the low at -$1.7 billion in Q4 2025.
• Average Non Operating Interest Expenses over 5 years is -$498.3 million, with a median of -$421.0 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses soared 54.6% in 2024, then plunged 296.04% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at -$360.0 million in 2022, then slumped by 162.5% to -$945.0 million in 2023, then soared by 54.6% to -$429.0 million in 2024, then slumped by 296.04% to -$1.7 billion in 2025, then soared by 74.4% to -$435.0 million in 2026.
• The last three Non Operating Interest Expenses figures came in at -$435.0 million (Q2 2026), -$393.0 million (Q1 2026), and -$1.7 billion (Q4 2025), per Business Quant data.